Abstract
Galacto-RGD is used for imaging angiogenesis.
Access provided by Autonomous University of Puebla. Download chapter PDF
Chemical name, alternative names | Chemical structure |
|---|---|
Cyclo [l-arginylglycyl-l-α-aspartyl-d-phenylalanyl-N6-[2,6-anhydro-7-deoxy-7-[[2-fluoro-1-oxopropyl]amino]-l-glycero-l-galacto-heptonoyl]-l-lysyl] |
|
Route of Synthesis
Two-step synthesis from 18F-fluoride with initial production of 18F propionate prosthetic group then coupling to galacto-RGD (Haubner et al. 2004).
Normal Biodistribution and Excretion
Rapid clearance from blood pool with primarily renal excretion. Low background activity in lungs and muscle.
Activity Administered
200 MBq.
Radiation Dosimetry
Effective dose equivalent (mSv/MBq): 0.019 (4 mSv/200 MBq).
Organ doses (mGy/MBq): bladder wall, 0.22; kidneys, 0.03; liver, 0.02 (Beer et al. 2006).
Patient Preparation
No specific preparation.
Clinical Utility
Imaging of angiogenesis. Has been evaluated in sarcoma, melanoma, renal cell cancer, head and neck, breast cancer, and glioblastoma multiforme. Detection of primary tumour is high, but lower detection rate for lymph nodes and distant metastases. Also taken up in some chronic inflammatory lesions (Beer et al. 2007; Haubner et al. 2014).
Further Reading
Beer AJ, Grosu AL, Carlsen J, et al. [18F]Galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6.
Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alphav beta3 expression. J Nucl Med. 2006;47:763–9.
Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61–9.
Haubner R, Maschauer S, Prante O. PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int. 2014;2014:871609.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ballinger, J.R. (2022). 18F-Galacto-RGD. In: PET Radiopharmaceuticals. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-031-10271-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-10271-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-10270-7
Online ISBN: 978-3-031-10271-4
eBook Packages: MedicineMedicine (R0)